Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a study of ALT-100 mAb in human subjects with Progressive Pulmonary Fibrosis (PPF)

Next Previous
Trial Profile

A Phase 2a study of ALT-100 mAb in human subjects with Progressive Pulmonary Fibrosis (PPF)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALT 100 (Primary)
  • Indications Pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms PAISANO

Most Recent Events

  • 08 Jan 2026 New trial record
  • 22 Dec 2025 According to a Aqualung Therapeutics media release, the Food and Drug Administration (FDA) has cleared IND application for Phase 2a study of ALT-100 mAb as an anti-inflammatory and anti-fibrotic therapy in human subjects with Progressive Pulmonary Fibrosis (PPF). Upon the next round of funding, the company will initiate this trial. The FDA waived the requirement for a prior idiopathic pulmonary fibrosis study due to compelling preclinical evidence and clinical safety evidence.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top